

1 **Role of monocytes in endothelial glycocalyx shedding during Puumala orthohantavirus** 2 **infection**

3

4 Luz E. Cabrera^{1*}, Isaac Polanco², Johanna Tietäväinen^{3,4}, Satu Mäkelä^{3,4}, Olli Vapalahti^{1,5},
5 Antti Vaheri¹, Jukka Mustonen^{3,4} and Tomas Strandin^{1,5}

6

7 ¹*Viral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki, Finland.*

8 ²*Universidad Iberoamericana (UNIBE), Santo Domingo, Dominican Republic.*

9 ³*Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.*

10 ⁴*Department of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland.*

11 ⁵*Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.*

12

13 **Corresponding author.*

14

15 **Abstract**

16 Vascular leakage characterizes Puumala orthohantavirus (PUUV)-caused hemorrhagic fever
17 with renal syndrome (HFRS). Disruption in the endothelial glycocalyx layer, which protects
18 blood vessels from increased vascular leakage into tissues, may contribute to disease severity
19 during acute PUUV-HFRS. Recent evidence suggests that increased heparanase (HPSE)
20 activity could play a role in glycocalyx degradation. Additionally, dynamic changes in
21 monocyte populations, especially a decrease in endothelium “patrolling” CD14⁺CD16⁺
22 nonclassical monocytes (NCMs) are observed in acute PUUV-HFRS. To investigate HPSE
23 expression levels in different monocyte subsets and their relationship to the numbers of
24 circulating endothelial cells (CECs) as marker of glycocalyx degradation during PUUV-HFRS,
25 we analyzed patient peripheral blood mononuclear cells collected at acute and recovery stages
26 of the disease by flow cytometry. CECs were significantly increased in acute PUUV-HFRS

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 patients, and gradually decreased towards the postacute and recovery phases. Moreover, we
28 identified significant correlations between CECs, the frequencies of different monocyte subsets
29 and their HPSE expression, and clinical parameters. The decrease in HPSE expressing NCMs
30 correlated with plasma HPSE levels, indicating a potential role for monocytes in modulating
31 endothelial glycocalyx shedding. Furthermore, co-culture experiments suggested PUUV-
32 infected endothelial cells (ECs) as regulators of monocyte HPSE expression. The study
33 enhances understanding of EC and monocyte dynamics during PUUV-HFRS, providing
34 insights into immune responses and potential vascular complications. Subtle variations in
35 monocyte subsets emphasize their possible variable roles in disease progression and changes
36 throughout the disease course. Overall, the study contributes to unraveling the complex
37 interactions between viral infections, immune responses, and vascular dynamics, guiding
38 future investigations and interventions in PUUV-HFRS-associated vascular complications and
39 glycocalyx shedding in the kidneys.

40 **Introduction**

41

42 The dynamic interplay between viral infections and the vascular system has been a subject of
43 increasing interest, particularly in the context of viral diseases with diverse clinical
44 manifestations (Fosse et al., 2021). Among these we find Puumala virus (PUUV), which causes
45 a relatively mild form of hemorrhagic fever with renal syndrome (HFRS) (Vaheri et al., 2023).
46 Despite the non-cytopathic effect of PUUV infection in endothelial cells (EC) and monocytes
47 (Temonen et al., 1993), which play a key role in vascular integrity, the infection leads to
48 remarkable vascular complications evidenced by capillary permeability, increased coagulation
49 and fibrinolysis, thrombocytopenia and shedding of the endothelial glycocalyx (EGC)
50 components (Hepojoki et al., 2014).

51

52 The EGC disruption is proposed as a potential factor driving capillary leakage in acute HFRS
53 (Connolly-Andersen et al., 2014; Tietäväinen et al., 2021; Du et al., 2023). The EGC acts as a
54 crucial interface between circulating blood components and the endothelium (Reitsma et al.,
55 2007), maintaining the vascular integrity and influencing its permeability. The enzyme
56 heparanase (HPSE) cleaves heparan sulfate molecules and acts as a major mediator in the
57 degradation of the EGC (Becker et al., 2015; Masola et al., 2022). The role of HPSE in
58 compromising vascular integrity in viral diseases has been recognized, including PUUV-HFRS
59 (Kinaneh et al., 2021; Cabrera et al., 2022; Drost et al., 2022). Further, EGC damage has been
60 proposed as a mechanism linking hyperglycemia with disease severity in HFRS (Tietäväinen
61 et al., 2021). During other viral diseases such as COVID-19, altered vascular permeability may
62 be responsible in the detachment of ECs associated with disease severity (Guervilly et al., 2020;
63 Varga et al., 2020; Kinaneh et al., 2021; Drost et al., 2022). This detachment not only facilitates
64 the dissemination of the virus but also impairs vascular reactivity and nitric oxide (NO)

65 production, crucial for blood vessel relaxation and vascular homeostasis by preventing
66 coagulation and inflammation.

67

68 Monocytes, as key players in the immune response, exhibit remarkable heterogeneity, with
69 distinct subsets playing different roles in immune response modulation, tissue homeostasis, and
70 pathogen defense (Williams et al., 2023). Notably, distinct monocyte subsets assume varying
71 roles in both steady-state and pathological conditions. Classical monocytes (CM, expressing
72 $CD14^{++}CD16^{-}$) primarily initiate innate immune responses, engaging in phagocytosis and
73 migration through the expression of chemokines, scavenger receptors, and proinflammatory
74 cytokines (Gren et al., 2015). Intermediate monocytes (IM, $CD14^{++}CD16^{+}$), on the other hand,
75 are linked to antigen processing, presentation, monocyte activation, inflammation, and
76 differentiation (Zawada et al., 2011), and nonclassical monocytes (NCM, $CD14^{+}CD16^{+}$), are
77 unique in their patrolling behavior, particularly in surveilling vasculature and thus interacting
78 with the endothelium (Cros et al., 2010). Importantly, monocyte translocation through vascular
79 bed requires EGC degradation mediated by HPSE, which is expressed on monocyte cell surface
80 (Sasaki et al., 2004) and suggests that monocytes are major source of HPSE activity.

81

82 In the context of acute PUUV-HFRS, our previous research revealed dynamic changes in
83 monocyte populations. NCMs are significantly diminished in the circulation during acute
84 PUUV-HFRS by rapidly redistributing to affected tissues during infection, accompanied by an
85 increase in CMs and IMs in blood (Vangeti et al., 2021). This NCM redistribution leads to
86 inflammation and tissue damage, particularly in the kidneys during acute PUUV-HFRS,
87 suggesting their involvement in renal pathology.

88

89 In the present study, we hypothesized that monocyte populations may play a crucial role in the
90 increased expression of HPSE, thereby contributing to the breakdown of the endothelial
91 glycocalyx and exacerbating vascular complications in PUUV-HFRS (Sironen et al., 2017). By
92 investigating the intricate mechanisms involving monocyte subsets and HPSE expression, our
93 research aims to shed light on the complex interplay between immune responses and vascular
94 complications during PUUV infection. These findings not only contribute to a deeper
95 understanding of the pathophysiology of this disease, but also lay the foundation for potential
96 therapeutic interventions in the future, to alleviate the vascular complications associated with
97 this viral illness.
98

99 **Materials & Methods**

100

101 **Ethics statement.** The Ethics Committees of Tampere University Hospital (permit number
102 R04180) and Hospital District of Helsinki and Uusimaa 100 (HUS/853/2020, HUS/1238/2020)
103 approved the use of patient samples. All subjects gave written informed consent in accordance
104 with the Declaration of Helsinki.

105

106 **Patient population.** The study material consisted of plasma, urine, and PBMCs from
107 hospitalized, serologically confirmed acute PUUV infection at Tampere University Hospital,
108 Finland, between 2005 and 2009. Patient samples were collected from a cohort of 25
109 individuals at different time points, which included the acute phase of the disease for samples
110 taken during hospitalization, the postacute/convalescent phase for samples taken 15 days after
111 discharge, and the full recovery phase for samples taken 6 months and one year after the acute
112 phase. Full recovery phase samples were used as controls. Standard methods were employed
113 to determine daily white blood cell (WBC) count, plasma C-reactive protein (CRP), and serum
114 creatinine concentrations at the Laboratory Centre of the Pirkanmaa Hospital District
115 (Tampere, Finland). Details about the clinical and laboratory data of the patient cohort can be
116 found in Table 1.

117 *Table 1. Clinical and laboratory data during hospitalization in patients with acute PUUV*
118 *infection. BP = blood pressure; WBC = white blood cells; max = maximum; min = minimum.*

119

Parameter (unit)	Range (Median \pm SD)	Reference values
PBMCs (n = 25)		
Age (years)	25 – 67 (40 \pm 13)	–
Gender (Male:Female)	15:10	–
After onset of fever (days)	3 – 7 (5 \pm 1)	–

Duration of fever (days)	3 – 9 (7 ± 2)	–
Length of hospital stay (days)	2 – 25 (4 ± 4.5)	
Max Systolic BP (mmHg)	102 – 208 (136 ± 26)	< 120
Max Diastolic BP (mmHg)	57 – 103 (84 ± 112)	< 80
Min Systolic BP (mmHg)	74 – 139 (110 ± 14)	< 120
Min Diastolic BP (mmHg)	40 – 93 (67 ± 12)	–
Max plasma creatinine ($\mu\text{mol/L}$)	51 – 1499 (137 ± 302)	Male: 62 – 115 / Female: 53 – 97
Max Hematocrit (%)	36 – 52 (44 ± 5)	Male: 39 – 50 / Female: 35 – 46
Min Hematocrit (%)	25 – 44 (36 ± 5)	Male: 39 – 50 / Female: 35 – 46
Max WBC ($\text{E}9/\text{L}$)	7 – 26 (11 ± 5)	3 – 8
Min Thrombocytes ($\text{E}9/\text{L}$)	15 – 118 (61 ± 29)	150 – 360
Weight change (kg)	0 – 10 (1 ± 3)	–
Max C-reactive protein (mg/L)	16 – 267 (89 ± 60)	< 4
Urinary albumin:creatinine ratio (mg/g)	0 – 61 (1 ± 12)	< 30

120

121 **Flow cytometry.** Frozen PUUV patient PBMCs were thawed in a 37°C water bath for 5 min,
 122 then washed with RPMI-1640 (Sigma Aldrich) supplemented with 10% inactivated FCS, 100
 123 IU/ml of penicillin, 100 $\mu\text{g/ml}$ of streptomycin, 2mM of L-glutamine, and 100 $\mu\text{g/ml}$ DNase I
 124 (Sigma Aldrich). After a 10 min incubation at RT, the cells were washed once with the
 125 conditioned medium and once with PBS-EDTA (PBS with 2 mM EDTA), followed by cell
 126 quantification using Bio-Rad cell counter TC20.

127 One to three million PBMCs were incubated in 1% FCS and FcR blocking reagent
 128 (BioLegend), and the cells stained for 30 min at RT with a cocktail of fluorescent-dye
 129 conjugated anti-human mouse mAbs recognizing cell surface antigens and a dead cell marker
 130 (antibody panel detailed in Table 2). After staining, the cells were washed with PBS-EDTA
 131 and fixed with 1% paraformaldehyde before FACS analysis with a 4-laser (405, 488, 561 and

132 637 nm) Quanteon Novocyte (Agilent Technologies). The FACS data was analyzed with
133 FlowJo 10.8. The datasets were normalized independently and concatenated. Cell populations
134 were identified by Uniform Manifold Approximation and Projection for Dimension Reduction
135 (UMAP), allowing for their unsupervised identification, based on the detection of different
136 fluorochromes used in the flow cytometry panel. To generate UMAP plots, the minimum
137 distance was set at 0.5 and the nearest neighbors' distance was set at 15, using a Euclidean
138 vector space. Clusters were then identified using the phenograph plugin.

139

140 *Table 2. Flow cytometry antibody panel.*

141

Marker	Fluorochrome	Clone	Company
CD123	PE	6H6	BioLegend
CD19	PE	LT19	Immunotools
CD3	PE	OKT3	BD Biosciences
CD56	PE	B159	BD Biosciences
Heparanase 1	FITC	HPA1 (E-10)	Santa Cruz Technology
Live/Dead	FVS 570	–	BD Biosciences
CD14	PE-Cy7	M5E2	BD Biosciences
CD34	APC	4H11	Invitrogen
CD45	V450	2D1	Invitrogen
CD133	Brilliant Violet 605	TMP4	Invitrogen
CD146	Brilliant Violet 711	P1H12	BioLegend
CD16	Brilliant Violet 786	3G8	BD Biosciences
HLA DR	BB700	G46-6	BD Biosciences
CD138	APC-CY7	44F9	MACS Miltenyi

142

143 ***In vitro* coculture.** Blood microvascular endothelial cells (BECs) were obtained from Lonza
144 and maintained in endothelial basal medium (EBM-2) supplemented with SingleQuots™ Kit
145 containing 5% fetal bovine serum (FBS), human endothelial growth factor, hydrocortisone,
146 vascular endothelial growth factor, human fibroblast growth factor-basic, ascorbic acid, R³-
147 insulin like growth factor-1, gentamicin and amphotericin-B (Lonza). For experiments the cells
148 were used at passage 8. BECs were infected for 3 days with live or UV-inactivated PUUV
149 (strain Suo). Multiplicity of infection was 1 as calculated by using Vero E6 cells. Monocytes
150 were isolated from PBMCs obtained from healthy volunteers using CD14 magnetic beads
151 (Miltenyi Biotec) according to the protocol provided by the manufacturer. Isolated monocytes
152 were co-cultured with infected BECs in a 3:1 ratio (with monocyte concentration of 1
153 million/ml) for 24-hr. Cell culture supernatant was collected after which cells were pelleted by
154 centrifugation 400g for 5 min and stained for flow cytometry as described above.

155

156 **ELISA.** Syndecan-1 was measured from urine of patients using an ELISA kit purchased from
157 R&D systems following the manufacturer's protocol (Human Syndecan-1 DuoSet, Catalog #:
158 DY2780; Bio-technie, Abingdon, UK).

159

160 **HPSE Measurement Assay.** HPSE levels from patient plasma and urine was measured
161 through the enzyme's ability to cleave HS, which was quantified with the use of a standard
162 curve. In detail, Nunc maxisorp flat-bottom 96-well plates (Thermo scientific; Breda, The
163 Netherlands) were coated with 10 µg/mL heparan sulfate from bovine kidney (HSBK) (Sigma–
164 Aldrich; Zwijndrecht, The Netherlands) in coating buffer (3.3 M ammonium sulfate
165 ((NH₄)₂SO₄)), for 1h at 37 °C. Subsequently, plates were washed with PBS supplemented with
166 0.05% Tween 20 (PBST) and blocked with 1% BSA in PBS at RT. After blocking, plates were

167 washed with PBST, followed by a final washing step with PBS. Plasma and urine samples were
168 then incubated for 2 h at 37 °C, in a 1:4 dilution in HPSE buffer (50 mM citric acid–sodium
169 citrate, 50 mM NaCl, 1 mM CaCl₂ at pH 5.0). Next, plates were washed with PBST and
170 incubated with primary mouse anti–rat IgM HS antibody JM403 (Amsbio; Abingdon, United
171 Kingdom, cat. no. #370730–S, RRID: AB_10890960, 1 µg/mL in PBST) at RT for 1 h, washed
172 with PBST and then incubated with secondary goat anti–mouse IgM HRP antibody (Southern
173 Biotech; Uden, The Netherlands, cat. no. #1020–05, RRID: AB_2794201, 1:10,000 dilution in
174 PBST) for 1h at RT and washed with PBST once again. Finally, 3,3',5,5'–tetramethylbenzidine
175 (TMB) substrate (Sigma–Aldrich, Zwijndrecht, The Netherlands) was added to the plates, the
176 reaction was stopped by the addition of 0.5 M sulfuric acid, and absorbance was measured at
177 450 nm. The HPSE concentration in the plasma and urine of patient samples, as well as from
178 podocyte cultures, was compared to a standard curve of recombinant human HPSE (Bio-
179 techne; Abingdon, UK, Cat#7570–GH–005). Urine concentrations measured were then
180 normalized by dividing the values by creatinine (heparanase:creatinine ratio).

181

182 **Statistical analyses.** Statistical analyses were performed using GraphPad Prism 8.3 software
183 (GraphPad Software, San Diego, CA, USA). Statistically significant correlations between
184 parameters were assessed by calculating Spearman's correlation coefficients, and differences
185 between groups were assessed with Kruskal-Wallis or ordinary 2-way ANOVA analyses,
186 depending on sample distribution and the number of groups analyzed.

187

188

189 **Results**

190 **Circulating mature and progenitor endothelial cells are increased during acute PUUV-** 191 **HFRS**

192

193 Quantitative analysis of peripheral blood mononuclear cells (PBMCs) using flow cytometry
194 (gating strategy shown in Fig. 1A) revealed dynamic alterations in endothelial cell (EC) counts
195 across different stages of PUUV-HFRS. During the acute phase of PUUV-HFRS (sampling at
196 1st day of hospitalization), a statistically significant increase in EC counts (both circulating
197 endothelial cells, CECs, and circulating endothelial progenitors, CEPs, Fig. 1B-C) was
198 observed compared to healthy recovery stage (12 months post-infection). The EC counts then
199 gradually decreased in the postacute phase but remained slightly elevated compared to disease
200 resolution. Notably, in the recovery stages at 6 months and 12 months post-infection, EC counts
201 reached their lowest levels, with no significant difference between these two time points. These
202 data suggest compromised endothelial integrity in PUUV-HFRS.

203

204 The acute PUUV-HFRS patient samples were further stratified based on days after onset of
205 fever (aof) at the time when samples were collected. This allowed us to observe kinetic
206 differences between CEC and CEP responses (Fig. 1D-E). Surprisingly, the peak increase in
207 CEPs occurred earlier as compared to CECs (5 vs. 7 days aof), which suggests either that
208 vascular integrity is being compromised before detectable CEC response occurs in our assay
209 or that CEPs mature directly into CECs during acute PUUV-HFRS.

210

211

212

213 **Dynamic modulation of monocyte subpopulations and HPSE expression during PUUV**
214 **infection**

215

216 Following the identification of monocytes using flow cytometry gating (Supplementary Figure
217 1), these immune cells were gated further into their well-known subpopulations of classical,
218 intermediate, and nonclassical monocytes (CM, IM and NCM, respectively), based on their
219 CD14 and CD16 expression (Figure 2A). Moreover, the assessment of their frequency changes
220 across different stages of PUUV-HFRS revealed a significant decrease in the frequency of
221 NCM during acute PUUV-HFRS, similarly as previously published (Vangeti et al., 2021),
222 compared to all the other groups (Figure 2A-B). Meanwhile, no visible distinctions are
223 observed in IM and CM frequencies between the PUUV-HFRS groups, with CMs showing
224 consistently high frequencies in all groups.

225

226 Additionally, the analysis of HPSE expression in monocyte subpopulations displayed distinct
227 patterns. Samples from acute PUUV infection exhibited significantly lower HPSE expression
228 in NCM, compared to postacute and recovery stages of the disease. However, no significant
229 differences are observed between PUUV-HFRS stages in IM. For CM, HPSE expression
230 remained consistently high across all disease stages, with no significant differences observed.

231

232 These findings suggest a dynamic modulation of monocyte subpopulations and HPSE
233 expression during viral infections. The pronounced decrease in NCM frequency and HPSE
234 expression in acute PUUV-HFRS compared to postacute and recovery stages underscores the
235 complexity of the immune response.

236

237

238 **Association between monocyte responses, HPSE expression and EC shedding during**
239 **acute PUUV-HFRS**

240

241 To gain further understanding between the relationships of monocyte responses and EGC
242 shedding, we investigated the associations between monocyte frequencies, their HPSE surface
243 expression, ECs (including both CECs and CEPs), soluble plasma HPSE levels and urinary
244 HPSE and syndecan-1 (a heparan sulfate proteoglycan and substrate for HPSE) levels during
245 acute PUUV-HFRS. The data for the latter three parameters was published previously (Cabrera
246 et al., 2022). Our findings revealed a significant association between monocyte distribution and
247 plasma HPSE levels. Decreased frequencies of CMs and increased frequencies of IMs and
248 NCMs associated with increased soluble HPSE levels by spearman correlation analysis, which
249 was corroborated by regression analysis for CM and IM (Fig. 3A-C). Furthermore, increased
250 frequencies of NCMs associated with increased frequencies of ECs, while the NCM surface
251 expression of HPSE associated with less ECs and increased urinary syndecan levels (Fig. 3D-
252 F). While the simultaneous loss of NCMs from the circulation makes the interpretation the
253 observed significant associations rather complex, these findings suggested that NCMs (and
254 potentially IMs) shed HPSE during acute PUUV-HFRS, which resulted in increased soluble
255 HPSE levels, increased numbers of ECs and increased amounts of EGC components in the
256 urine. We also analyzed the potential association between EC, monocyte subpopulations and
257 their HPSE expression with several clinical parameters (Supplementary Fig. 2A) and found that
258 NCM not only correlated with disease severity, as previously suggested (Vangeti et al., 2021),
259 but could also explain 19.81% of the variance in disease severity ($R^2 = 0.1981$, p value =
260 0.0258) (Supplementary Fig. 2B). Moreover, a higher frequency of HPSE-expressing NCMs
261 in circulation was strongly linked to less hypotension (Supplementary Fig. 2C-D). On the other
262 hand, although HPSE-expressing CMs correlated with a few clinical parameters, the deeper

263 analyses of these associations through simple linear regressions were not as significant
264 (Supplementary Fig. 2E-G).

265

266

267 **Downregulation of monocyte surface HPSE expression is mediated by PUUV-infected** 268 **ECs**

269

270 The observed modulation of HPSE expression in monocyte subsets during acute PUUV-HFRS
271 led us to investigate the direct effect of virus infection in monocyte HPSE expression. Since
272 PUUV is known to productively target ECs, we developed an assay in which isolated human
273 primary monocytes were co-cultured with infected primary ECs before analyzing the surface
274 expression of HPSE in different monocyte subsets as well as ECs by flow cytometry.
275 Approximately 10% of ECs infected with live PUUV but none by UV-inactivated PUUV
276 expressed PUUV nucleocapsid protein which confirmed the presence of virus in the co-culture
277 (Supplementary Fig. 3), prior to the addition of monocytes at 3 days post infection.
278 Interestingly, the surface expression of HPSE significantly diminished in CMs, IMs and NCMs
279 in infected co-cultures as compared to non-infected controls inoculated with UV-inactivated
280 virus (Fig. 4). This finding suggests that virus infection, either directly or indirectly, down-
281 regulated HPSE expression in monocytes. We observed a slight but non-significant
282 downregulation of HPSE expression also in infected ECs.

283

284

285 **Unsupervised clustering of monocyte populations in acute PUUV-HFRS**

286

287 Finally, we wanted to gain more insight into the distinct monocyte subpopulations during
288 PUUV-HFRS and employed unsupervised clustering of marker expression, including HPSE,

289 CD138, HLA-DR as well as the well-described CD16 and CD14. By these means we identified
290 18 distinct monocyte populations during PUUV-HFRS (Figure 5A). Clusters 1, 2, 6, 11, 14,
291 and 18 presented co-expression patterns indicative of IMs, since these clusters showed
292 increased CD16 expression while maintaining significant CD14 expression. These IM clusters
293 displayed variable HLA-DR expressions, suggesting a dynamic transition from CMs to IMs.
294 On the other hand, clusters 3, 4, 5, 7, 8, 9, 10, 12, 13, 15 and 16 exhibited a co-expression
295 pattern marked by higher CD14 levels, and a lack of CD16 expression, thus indicative of CMs.
296 Finally, cluster 17 stands out with elevated levels of CD16 together with a low CD14 marker
297 expression, suggesting a NCM phenotype.

298

299 When analyzing the trends in population changes during different disease stages, we discovered
300 that populations 1, 6, and 14, identified as IMs, showed increased frequencies during both acute
301 and postacute phases (Figure 5B), while other IM populations were either increased during the
302 acute phase (population 11, Figure 5C), or during the postacute phase (populations 2, 8, and
303 10, Figure 5D). Meanwhile, populations 3, 7, 13, 16, 17, and 18, identified as CMs and NCMs,
304 exhibited decreased frequencies during acute illness (Figure 5C), possibly reflecting their
305 redistribution, as previously described for NCMs (Vangeti et al., 2021), and indicating their
306 potential involvement in response to viral infection. In contrast, populations 9, 12, and 15,
307 identified as CMs, decreased during the postacute phase (Figure 5D), indicating potential shifts
308 in monocyte subsets as the disease evolved.

309

310

311

312

313

314 **Discussion**

315

316 Investigation of the role of ECs in PUUV-HFRS is critically important, considering their
317 central involvement in vascular responses. ECs play a pivotal role in maintaining vascular
318 integrity, and their dynamic alterations during viral infections can offer crucial insights into the
319 pathophysiological processes. This study aimed to unravel the complex interplay between
320 PUUV infection, innate immune responses, and vascular dynamics by exploring the presence
321 of CECs as marker of EGC degradation and the potential effect monocytes may have on EGC
322 degradation in the circulation of patients during PUUV-HFRS. Our analysis unveiled an
323 evident increase in EC counts and diminished HPSE expression in monocytes during the acute
324 phase of PUUV-HFRS, which gradually returned to baseline levels towards the postacute and
325 recovery stages.

326

327 By showing increased levels of CECs and CEPs in acute PUUV-HFRS, our study indicates
328 that EC integrity is compromised during acute disease, as has been speculated by many
329 previous reports (reviewed in (Vaheri et al., 2023)). To our knowledge, this is the first report
330 indicating increased CECs in orthohantavirus-caused disease but is in line with previous reports
331 showing increased levels of circulating EGC components such as syndecan-1 and increased
332 HPSE activity in urine of acute PUUV-HFRS (Connolly-Andersen et al., 2014; Cabrera et al.,
333 2022). Moreover, the persistence of slightly elevated EC counts in postacute PUUV-HFRS
334 suggests ongoing vascular involvement and points towards delayed resolution of vascular
335 damage. The subsequent declining trend in EC counts during the recovery phases may signify
336 a resolution of acute endothelial damage, possibly through the restoration of endothelial
337 integrity or clearance of damaged cells.

338

339 A previous study indicated a significant increase in CEPs during the late acute PUUV-HFRS,
340 which is associated with disease severity (Krautkrämer et al., 2014). In contrast to our study,
341 in which we observed the peak of CEP response in the early acute phase (5 days post onset of
342 clinical symptoms), the peak in the CEP response was observed at late acute stage (11-13 days
343 post onset of clinical symptoms). This apparent discrepancy may be due to the differences in
344 the cellular markers used to identify CEPs. Specifically, in our study we classified CEPs as
345 being negative for CD146 despite a previous report indicates that CD146 can be expressed in
346 a subset of CEPs (Delorme et al., 2005). Therefore, our data may underestimate the actual CEP
347 counts and at least partially explain these discrepant data.

348

349 Monocytes and their diverse subpopulations play a pivotal role in immune surveillance and
350 response. To explore the origin of CECs, we inspected monocyte subpopulations and their
351 HPSE expression during PUUV infection and recovery. Employing a comprehensive gating
352 strategy, we identified dynamic changes in CM, IM and NCM monocyte frequencies across
353 different stages of PUUV-HFRS, highlighting the complex nature of monocyte responses
354 during viral infections. Particularly, the observed decrease in NCM frequency during acute
355 PUUV-HFRS, which were strongly associated with disease severity, corroborates our previous
356 findings (Vangeti et al., 2021) where we documented NCM redistribution from circulation to
357 affected organs, such as the kidneys, and prompting consideration of the potential local effects
358 of these cells. Interestingly, previous studies on viral diseases have revealed a similar decrease
359 of NCM frequencies during severe COVID-19 (Silvin et al., 2020).

360

361 Our further analysis revealed diminished frequencies of HPSE⁺ NCMs in acute PUUV-HFRS.
362 Furthermore, correlation and regression analyses, particularly those involving NCM
363 frequencies and their HPSE expression, revealed a positive association with plasma HPSE

364 activity and negative association with ECs, respectively, implying a potential role of these cells
365 in modulating endothelial responses. This was further supported by the strong power of HPSE-
366 expressing NCMs in influencing blood pressure. These findings are in line with the idea that
367 once NCMs encounter PUUV-infected ECs, their surface expressed HPSE is released to
368 degrade the EGC. Consequently, this degradation could manifest as increased frequencies of
369 CECs and increased EC permeability.

370

371 The decreased monocyte HPSE expression by PUUV infection was further corroborated by *in*
372 *vitro* co-culture experiments involving PUUV-infected ECs and monocytes. These findings
373 demonstrate that the downregulation of monocyte HPSE during HFRS is likely mediated by
374 the virus. Our data does not, however, pinpoint the exact mechanism of HPSE downregulation,
375 which based on the current results could be caused by monocytes directly encountering the
376 virus or by indirect mechanisms mediated by infection-activated ECs. The latter seems more
377 likely due to our previous studies, which indicate increased leukocyte (monocytes and
378 neutrophils) adhesive ability of PUUV-infected ECs as compared to non-infected ECs
379 (Strandin et al., 2018; Vangeti et al., 2021). One argument against the role of virus particles
380 per se in HPSE downregulation is also the strong downregulation of PUUV infection in the *in*
381 *vitro* infected ECs at the 3-day post infection time point, when monocytes were added to the
382 culture. Only 10 % of ECs showed antigen positivity at this time point, which is significantly
383 less than the initial level of PUUV infection at 1-day time point, as shown previously (Strandin
384 et al., 2016). The decrease in PUUV infection is due to cellular antiviral responses, which could
385 also affect monocyte HPSE expression in co-culture assay setup.

386

387 Unsupervised analysis based on surface marker expression elucidated distinct coexpression
388 patterns indicative of CMs, IMs, and NCMs. Monocyte populations exhibiting increased CD16

389 expression and variable HLA-DR levels were identified as IMs, and their increased frequencies
390 mostly prevailed during both acute and postacute phases, suggesting potential early-stage
391 involvement. This is in line with our previous study, in which we observed strongly increased
392 HLA-DR expression in total IM cell subset in acute PUUV-HFRS (Vangeti et al., 2021).
393 However, it is important to note that this was specific to certain IM clusters identified through
394 phenograph analysis, but not all, since frequencies of certain IM clusters were increased during
395 the postacute phase. It's crucial to consider these dynamics in the context of the identified
396 monocyte subsets and their distinct roles during PUUV-HFRS progression.

397

398 While the overall frequencies of CMs demonstrate relative stability across different disease
399 stages, our detailed analysis reveals population-specific dynamics within CM subsets. Notably,
400 populations 9, 12, and 15, identified as CMs, show decreased frequencies during the postacute
401 phase, suggesting potential shifts in these specific CM subsets as the disease progresses. This
402 nuanced observation highlights the need for a more granular understanding of the distinct
403 responses within CM populations to comprehensively unravel their roles in PUUV-HFRS
404 pathogenesis. Despite valuable insights, a limitation of this study is the lack of tissue-specific
405 analyses, which would offer a more comprehensive understanding.

406

407 In conclusion, our study contributes to a better understanding of PUUV-HFRS
408 immunopathogenesis by unraveling EC and monocyte subpopulation dynamics. Observed
409 changes underscore multi-faceted host responses during viral infections, paving the way for
410 research on vascular complications and potential therapeutic interventions. The comprehensive
411 investigation into EC and monocyte dynamics during PUUV-HFRS provides insights into the
412 complex interplay between viral infections, immune responses, and vascular alterations. This
413 investigation prompts additional exploration of the distinct roles played by monocyte subsets

414 in endothelial responses, offering opportunities for interventions in vascular complications
415 linked to PUUV-HFRS. Delving into the contributions of monocytes to endothelial glycocalyx
416 shredding during PUUV infection carries significant clinical implications, as it unveils
417 mechanisms that could be contributing to both vascular leakage and renal damage in HFRS.
418 Therefore, these insights may lead to the identification of novel targets for addressing these
419 complex clinical challenges.

420

421 **Declaration of Competing Interest**

422 All authors declare no financial competing interests related to the study.

423

424 **Acknowledgements**

425 This work was financed by grants by the Academy of Finland to T.S. (321809); grants by the

426 Helsinki University Hospital funds to O.V. (TYH 2021343); EU Horizon 2020 programme

427 VEO (874735) to O.V.; Paulon Säätiö to L.E.C.; Suomen Lääketieteen Säätiö to L.E.C.;

428 Finnish Kidney Foundation to L.E.C. and J.T.; Jane and Aatos Erkkö foundation to O.V.; and

429 Finnish Cultural Foundation Pirkanmaa Regional fund to J.T. The funders had no role in study

430 design, data collection and analysis, nor decision to publish, or preparation of the manuscript.

431 The authors also thank S. Mäki and M. Utriainen for expert technical assistance.

432 **References**

433

434 Becker, B. F., Jacob, M., Leipert, S., Salmon, A. H. J., and Chappell, D. (2015). Degradation of the
435 endothelial glycocalyx in clinical settings: Searching for the sheddases. *Br J Clin Pharmacol* 80,
436 389–402. doi: 10.1111/bcp.12629

437

438 Cabrera, L. E., Schmotz, C., Saleem, M. A., Lehtonen, S., Vapalahti, O., Vaheri, A., et al. (2022).
439 Increased Heparanase levels in urine during acute Puumala Orthohantavirus infection are associated
440 with disease severity. *Viruses* 14. doi: 10.3390/v14030450

441

442 Connolly-Andersen, A. M., Thunberg, T., and Ahlm, C. (2014). Endothelial activation and repair during
443 hantavirus infection: Association with disease outcome. *Open Forum Infect Dis* 1. doi:
444 10.1093/ofid/ofu027

445

446 Cros, J., Cagnard, N., Woollard, K., Patey, N., Zhang, S. Y., Senechal, B., et al. (2010). Human CD14dim
447 Monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. *Immunity* 33,
448 375–386. doi: 10.1016/j.immuni.2010.08.012

449

450 Delorme, B., Basire, A., Gentile, C., Sabatier, F., Monsonis, F., Desouches, C., et al. (2005). Presence of
451 endothelial progenitor cells, distinct from mature endothelial cells, within CD146+ blood cells.
452 *Thromb Haemost* 94, 1270–1279. doi: 10.1160/TH05-07-0499

453

454 Drost, C. C., Rovas, A., Osiaevi, I., Rauen, M., van der Vlag, J., Buijsters, B., et al. (2022). Heparanase Is
455 a putative mediator of endothelial glycocalyx damage in COVID-19 – A proof-of-concept study.
456 *Front Immunol* 13. doi: 10.3389/fimmu.2022.916512

457

458 Du, H., Hu, H., Li, J., Wang, X., Jiang, H., Lian, J., et al. (2023). High levels of exfoliated fragments
459 following glycocalyx destruction in hemorrhagic fever with the renal syndrome are associated with
460 mortality risk. *Front Med (Lausanne)* 10. doi: 10.3389/fmed.2023.1096353






461

- 462 Fosse, J. H., Haraldsen, G., Falk, K., and Edelmann, R. (2021). Endothelial cells in emerging viral
463 infections. *Front Cardiovasc Med* 8. doi: 10.3389/fcvm.2021.619690
464
- 465 Gren, S. T., Rasmussen, T. B., Janciauskiene, S., Hakansson, K., Gerwien, J. G., and Grip, O. (2015). A
466 single-cell gene-expression profile reveals inter-cellular heterogeneity within human monocyte
467 subsets. *PLoS One* 10. doi: 10.1371/journal.pone.0144351
468
- 469 Guervilly, C., Burtey, S., Sabatier, F., Cauchois, R., Lano, G., Abdili, E., et al. (2020). Circulating
470 Endothelial Cells as a marker of endothelial injury in severe COVID-19. *Journal of Infectious
471 Diseases* 222, 1789–1793. doi: 10.1093/infdis/jiaa528
472
- 473 Hepojoki, J., Vaheri, A., and Strandin, T. (2014). The fundamental role of endothelial cells in hantavirus
474 pathogenesis. *Front Microbiol* 5. doi: 10.3389/fmicb.2014.00727
475
- 476 Kinaneh, S., Khamaysi, I., Karram, T., and Hamoud, S. (2021). Heparanase as a potential player in SARS-
477 CoV-2 infection and induced coagulopathy. *Biosci Rep* 41. doi: 10.1042/BSR20210290
478
- 479 Krautkrämer, E., Grouls, S., Hettwer, D., Rafat, N., Tönshoff, B., and Zeier, M. (2014). Mobilization of
480 circulating endothelial progenitor cells correlates with the clinical course of Hantavirus disease. *J
481 Virol* 88, 483–489. doi: 10.1128/jvi.02063-13
482
- 483 Masola, V., Greco, N., Gambaro, G., Franchi, M., and Onisto, M. (2022). Heparanase as active player in
484 endothelial glycocalyx remodeling. *Matrix Biol Plus* 13. doi: 10.1016/j.mbplus.2021.100097
485
- 486 Reitsma, S., Slaaf, D. W., Vink, H., Van Zandvoort, M. A. M. J., and Oude Egbrink, M. G. A. (2007).
487 The endothelial glycocalyx: Composition, functions, and visualization. *Pflugers Arch* 454, 345–
488 359. doi: 10.1007/s00424-007-0212-8
489

- 490 Sasaki, N., Higashi, N., Taka, T., Nakajima, M., and Irimura, T. (2004). Cell surface localization of
491 Heparanase on Macrophages regulates degradation of extracellular matrix Heparan Sulfate. *The*
492 *Journal of Immunology* 172, 3830–3835. doi: 10.4049/jimmunol.172.6.3830
493
- 494 Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A. G., Dubuisson, A., Derosa, L., et al. (2020). Elevated
495 calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. *Cell* 182,
496 1401-1418.e18. doi: 10.1016/j.cell.2020.08.002
497
- 498 Sironen, T., Sane, J., Lokki, M. L., Meri, S., Andersson, L. C., Hautala, T., et al. (2017). Fatal Puumala
499 hantavirus disease: Involvement of complement activation and vascular leakage in the pathobiology.
500 *Open Forum Infect Dis* 4. doi: 10.1093/ofid/ofx229
501
- 502 Strandin, T., Hepojoki, J., Laine, O., Mäkelä, S., Klingström, J., Lundkvist, A., et al. (2016). Interferons
503 induce STAT1-dependent expression of Tissue Plasminogen Activator, a pathogenicity factor in
504 Puumala Hantavirus disease. *Journal of Infectious Diseases* 213, 1632–1641. doi:
505 10.1093/infdis/jiv764
506
- 507 Strandin, T., Mäkelä, S., Mustonen, J., and Vaheri, A. (2018). Neutrophil activation in acute hemorrhagic
508 fever with renal syndrome is mediated by hantavirus-infected microvascular endothelial cells. *Front*
509 *Immunol* 9. doi: 10.3389/fimmu.2018.02098
510
- 511 Temonen, M., Vapalahti, O., Holthöfer, H., Brummer-Korvenkontio, M., Vaherp, A., and Lankinen, H.
512 (1993). Susceptibility of human cells to Puumala virus infection. *Journal of General Virology* 74,
513 515–518.
514
- 515 Tietäväinen, J., Mäkelä, S., Huhtala, H., Pörsti, I. H., Strandin, T., Vaheri, A., et al. (2021). The clinical
516 presentation of Puumala Hantavirus induced Hemorrhagic Fever with Renal Syndrome Is related to
517 plasma glucose concentration. *Viruses* 13, 1177. doi: 10.3390/v13061177
518

- 519 Vaheri, A., Smura, T., Vauhkonen, H., Hepojoki, J., Sironen, T., Strandin, T., et al. (2023). Puumala
520 Hantavirus infections show extensive variation in clinical outcome. *Viruses* 15. doi:
521 10.3390/v15030805
522
- 523 Vangeti, S., Strandin, T., Liu, S., Tauriainen, J., Räisänen-Sokolowski, A., Cabrera, L. E., et al. (2021).
524 Monocyte subset redistribution from blood to kidneys in patients with Puumala virus caused
525 hemorrhagic fever with renal syndrome. *PLoS Pathog* 17. doi: 10.1371/journal.ppat.1009400
526
- 527 Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., et al. (2020).
528 Endothelial cell infection and endothelitis in COVID-19. *The Lancet* 395, 1417–1418. doi:
529 10.1016/S0140-6736(20)30937-5
530
- 531 Williams, H., Mack, C., Baraz, R., Marimuthu, R., Naralashetty, S., Li, S., et al. (2023). Monocyte
532 differentiation and heterogeneity: inter-subset and interindividual differences. *Int J Mol Sci* 24. doi:
533 10.3390/ijms24108757
534
- 535 Zawada, A. M., Rogacev, K. S., Rotter, B., Winter, P., Marell, R. R., Fliser, D., et al. (2011). SuperSAGE
536 evidence for CD14⁺⁺CD16⁺ monocytes as a third monocyte subset. *Blood* 118. doi: 10.1182/blood-
537 2011-01-326827
538
539

540 **Figures & figure legends**



542 **Figure 1. Identification and quantification of endothelial cells in acute PUUV-HFRS Patients.** (A) Flow
543 cytometry gating strategy for the identification of endothelial cells (ECs) from peripheral blood mononuclear cells
544 (PBMCs). The gating strategy involves a stepwise selection process, starting with morphological gating for debris
545 exclusion (FSC vs. SSC plot), followed by singlet gating to exclude doublets (FSC-A vs FSC-H), and a dump
546 channel for the exclusion of dead cells and CD3, CD56, CD19 expressing cell populations. Subsequently, a
547 double-negative gate for HLA-DR and CD16 is applied, followed by a CD14⁻/CD45^{-dim}, to ensure the exclusion
548 of background when identifying rare cells such as ECs. Then, the final gate plots CD133 and CD146 markers, to
549 identify the circulating EC populations of interest: CD133⁻/CD146⁺ for mature CECs and CD133⁺/CD146⁻ for
550 CEPs.

551 (B-C) Graph depicting individual counts of (B) Mature CD146⁺/CD133⁻ CECs and (C) CD146⁻/CD133⁺ CEPs
552 obtained from flow cytometry analysis. The x-axis illustrates different groups: acute, postacute, and recovered (6
553 months and 12 months post-infection) PUUV-HFRS patients. Each data point represents a CEC count from one
554 individual within the specified group.


555 (D-E) Timeline graphs of the (D) CEC and (E) CEP cell count means (\pm SD) from PUUV-infected patients during
556 acute, postacute, and recovery phases.

557 * $p < 0.05$; p values calculated with Kruskal-Wallis test.

558 *EC = endothelial cell; CEC = circulating endothelial cells; CEP = circulating endothelial progenitors; AOF =*
559 *after onset of fever; FSC = forward scatter; SSC = side scatter; PUUV = Puumala orthohantavirus; PUUV-*
560 *HFRS = Puumala orthohantavirus-caused hemorrhagic fever with renal syndrome; SD = standard deviation.*

561

562



563

564 **Figure 2. Monocyte subpopulation frequencies and HPSE expression in different stages of PUUV-HFRS.**

565 (A) Contour plots of all monocytes from concatenated PUUV-HFRS samples, depicting the distribution of

566 classical, intermediate and nonclassical monocyte subpopulations in acute, postacute, recovery (6- and 12-months

567 post-infection) stages of PUUV-HFRS. The quadrant gate depicts the variable frequencies of CM, IM, and NCM

568 in each disease stage. (B) Box plots illustrating the frequency distribution of CM, IM, and NCM across different

569 disease stages (acute, postacute, recovery including 6- and 12-months post-infection). The y-axis represents the

570 percentage of monocytes, with each subpopulation displayed in distinct colors. (C) Box plots showing the

571 expression levels of the HPSE surface marker in monocyte subpopulations across the different disease stages.


572 * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. P values calculated with 2-way ANOVA Tukey's multiple

573 comparisons test.


574 *PUUV-HFRS = Puumala orthohantavirus-caused hemorrhagic fever with renal syndrome; HPSE = heparanase;*

575 *CM = classical monocyte; IM = intermediate monocyte; NCM = nonclassical monocyte.*


A




B




C




D



E



F



576

577 **Figure 3. Multiparameter correlation analysis in PUUV-HFRS.** (A) Correlation matrix depicting the
 578 relationships between flow cytometry parameters, including EC counts (including both CECs and CEPs),
 579 monocyte subpopulation frequencies, and HPSE expression in monocytes, alongside measured syndecan-1 in
 580 urine and HPSE levels in plasma and urine and days AOF.

581 (B) Regression analysis demonstrating a negative association between the frequency of CM and plasma HPSE
582 levels.

583 (C) Regression analysis revealing a positive link between the frequency of IM and plasma HPSE levels.

584 (D) Positive regression analysis displaying the correlation between the frequency of NCM and EC counts from
585 flow cytometry.

586 (E) Regression analysis illustrating the negative correlation between the frequency of HPSE⁺ NCM and EC counts
587 from flow cytometry.

588 (F) Positive regression analysis between HPSE⁺ NCM and urinary syndecan:creatinine ratio.

589 P values were determined using Pearson correlation and are denoted as follows: *p < 0.05, **p < 0.01, ***p <
590 0.001.


591 *PUUV-HFRS = Puumala orthohantavirus-caused hemorrhagic fever with renal syndrome; HPSE = heparanase;*

592 *CM = Classical monocytes; NCM = Nonclassical monocytes; EC = endothelial cells; HPSE⁺ NCM =*

593 *heparanase-expressing nonclassical monocytes; U-syndecan/creatinine = urinary syndecan:creatinine ratio;*

594 *AOF = after onset of fever.*

595



596

597

598 **Figure 4. Heparanase expression is decreased in monocyte subpopulations by PUUV-infected endothelial**

599 **cells.** BECs were infected live or UV-inactivated PUUV for 3 days after which monocytes isolated from healthy

600 controls were introduced in the co-culture for 24-hr. Cells were stained with an antibody panel allowing the

601 identification of surface HPSE expression in CMs, IMs, NCMs and ECs by flow cytometry. The statistical

602 differences between UV- and live PUUV-infected co-cultures were assessed by Kruskal-Wallis test. * $p < 0.05$,


603 ** $p < 0.01$, *** $p < 0.001$.

604 *PUUV = Puumala orthohantavirus; HPSE+ = heparanase-expressing cell; BECs = blood microvascular*


605 *endothelial cells.*

606


A




B



C



D



607

608 **Figure 5. Unsupervised identification of monocyte subpopulations in PUUV-HFRS disease stages.** (A) A
 609 heatmap presenting the MFI of surface markers (HPSE, CD138, HLA-DR, CD16, and CD14) across 18 monocyte
 610 subpopulations identified through phenograph clustering analysis. Each row corresponds to a subpopulation, with
 611 color intensity indicating the MFI levels of the respective surface markers.

612 **(B–D)** Graphical representation showing the percentage of monocyte subpopulations during different disease
613 phases (acute, postacute, 6 months, and 12 months). Dots connected by line graphs indicate trends in
614 subpopulation changes.

615 **(B)** Changes in acute and postacute phases are seen in populations 1, 6, and 14 frequencies, which are increased
616 during these phases, compared to recovery.

617 **(C)** Changes during the acute phase of the disease are detected in populations 3, 7, 11, 13, 16, 17 and 18, where
618 the majority exhibit a decrease in frequency during this phase, while the frequency of population 11 shows an
619 increase.

620 **(D)** Graph displaying the percentage variations of monocyte subpopulations (pops 2, 8, 9, 10, 12, and 15) specific
621 to the postacute phase in comparison to other phases.

622 *MFI*= mean fluorescence intensity; *HPSE* = heparanase; *pop* = population; *PUUV-HFRS* = *Puumala*
623 *orthohantavirus-caused hemorrhagic fever with renal syndrome*.

624





625 **Supplementary figure legends**


626 **Supplementary Figure 1. Flow cytometry gating strategy for monocyte identification.** Flow cytometry gating
627 strategy outlining the stepwise selection process for identifying monocytes from PBMCs. The strategy consists of
628 six sequential gates to ensure accurate and specific identification: (a) Morphological gating (FSC vs. SSC plot) to
629 exclude debris. (b) Singlet gating to exclude doublets, by plotting FSC area vs. height. (c) Dump channel gate to
630 exclude dead cells and CD3, CD56, and CD19 expressing cell populations. (d) CD45 gating, where the CD45⁺
631 cell population is selected, represented by CD45 vs. side scatter (SSC) plot. (e) HLA-DR gating, isolating HLA-
632 DR⁺ cells with high side scatter (SSC) to capture monocytes within PBMCs. (f) CD14 vs. CD16 gating, excluding
633 double-negative cells in the CD14 vs. CD16 plot to specifically identify monocytes. *FSC = forward scatter; SSC*
634 *= side scatter; PBMC = peripheral blood mononuclear cell; FSC-A = forward scatter area; FSC-H = forward*
635 *scatter height.*

636


637 **Supplementary Figure 2. Correlation and regression analyses of ECs, monocyte subpopulations, HPSE**
638 **expression, and clinical parameters in PUUV-HFRS.** (A) Extended correlation matrix depicting the Spearman's
639 rank correlation coefficients between flow cytometry-derived monocyte subpopulation counts, their respective
640 HPSE expressions, plasma P-HPSE, urine U-HPSE:creat, U-syndecan-1:creat, and various clinical parameters.
641 Clinical parameters are located together and delimited by a black box, where significant correlations ($p < 0.05$) are
642 marked with a surrounding dashed line. (B-G) Simple linear regression analyses illustrating the relationships
643 between: (B) NCM frequency and disease severity score, (C) HPSE⁺ NCM frequency and minimum diastolic
644 blood pressure, (D) HPSE⁺ NCM frequency and minimum systolic blood pressure, (E) HPSE⁺ CM frequency and
645 maximum diuresis per day, (F) HPSE⁺ CM frequency and maximum systolic blood pressure, and (G) HPSE⁺ CM
646 frequency and duration of fever. *EC* = endothelial cells; *CM* = classical monocytes; *IM* = intermediate
647 monocytes; *NCM* = non-classical monocytes; *HPSE* = heparanase; *HPSE*⁺ = HPSE-expressing cells; *P-HPSE*
648 = plasma heparanase; *U-HPSE/creat* = urine heparanase:creatinine ratio; *U-syndecan-1/creat* = urine
649 syndecan-1:creatinine ratio; *LOS* = length of stay; *min* = minimum; *max* = maximum; *SBP* = systolic blood
650 pressure; *DBP* = diastolic blood pressure; *creat* = creatinine; *WBC* = white blood cells; *thromb* = thrombocytes;
651 *CRP* = C-reactive protein; *U-alb:creat* = urine albumin:creatinine ratio; *days AOF* = days after onset of fever.
652

653 **Supplementary Figure 3. Immunofluorescence of UV-inactivated PUUV and live PUUV-infected blood**
654 **microvascular endothelial cells (BECs) prior to coculture with monocytes.** BECs were infected with live or
655 UV-inactivated PUUV for 3 days and stained for PUUV nucleocapsid protein N and nucleus by PUUV N-specific
656 rabbit sera (green) and Hoechst33342 (blue), respectively. Overlay images of green and blue fluorescence are
657 shown. *UV = ultraviolet; PUUV = Puumala orthohantavirus; N = nucleocapsid; BEC = blood microvascular*
658 *endothelial cells.*
659


A**B****C****D**




A




B




C




D






E




F




A**B****C**


A




B




C




D



E




SSC




FSC

FSC-H




FSC-A

SSC




Dump

CD14




CD45

SSC











HLA-DR


CD14



CD16



UV-inactivated PUUV



Live PUUV

